Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: An NRG oncology/ gynecologic oncology group study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leiomyosarcoma
  • Uterine Neoplasms

abstract

  • The addition of bevacizumab to gemcitabine-docetaxel for first-line treatment of metastatic uLMS failed to improve PFS, OS, or ORR. Gemcitabine-docetaxel remains a standard first-line treatment for uLMS.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4372854

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.58.3781

PubMed ID

  • 25713428

Additional Document Info

start page

  • 1180

end page

  • 5

volume

  • 33

number

  • 10